Demographic and Baseline Clinical Characteristics of Patients With G3 NENs (n = 69)
| Characteristic | No. of patients | % of patients |
| Sex | ||
| Male | 41 | 59.4 |
| Female | 28 | 40.6 |
| Primary tumor site | ||
| Unknown | 11 | 15.9 |
| Pancreas | 46 | 66.7 |
| Stomach | 3 | 4.3 |
| Midgut | 6 | 8.7 |
| Rectum | 3 | 4.3 |
| Differentiation | ||
| Well differentiated | 11 | 15.9 |
| Moderately differentiated | 3 | 4.3 |
| Poorly differentiated | 28 | 40.6 |
| NA | 27 | 39.1 |
| Primary tumor resected | ||
| Yes | 25 | 36.2 |
| No | 44 | 63.8 |
| Ki-67 index | ||
| ≤55% | 53 | 76.8 |
| >55% | 11 | 15.9 |
| NA (>20) | 5 | 7.2 |
| Primary treatment before PRRT | ||
| Somatostatin analog | 17 | 24.6 |
| Chemotherapy | 35 | 50.7 |
| Temozolomide | 4 | 5.8 |
| Capecitabine–5-fluorouracil | 13 | 18.8 |
| Streptozocin | 5 | 7.2 |
| Doxorubicin | 4 | 5.8 |
| Cisplatin | 14 | 20.3 |
| Carboplatin | 8 | 11.6 |
| Etoposide | 16 | 23.2 |
| Oxaliplatin | 3 | 4.3 |
| Gemcitabine | 3 | 4.3 |
| Doxorubicin– cyclophosphamide– vincristine | 2 | 2.9 |
| Doxorubicin–vincristine– actinomycin | 1 | 1.2 |
| Interferon | 2 | 2.9 |
| Surgery | 34 | 49.3 |
| Liver-directed therapy | 11 | 15.9 |
| Radiofrequency ablation | 2 | 2.9 |
| Transarterial chemoembolization | 7 | 10.1 |
| Embolization | 2 | 2.9 |
| Selective internal radiation therapy (radioembolization) | 5 | 7.2 |
| External-beam radiotherapy | 5 | 7.2 |
NA = not available.
Patients were 58.1 ± 12.9 y old.